Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance

Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system. With its overall dismal prognosis (the median survival is 14 months), GBMs demonstrate a resounding resilience against all current treatment modalities. The absence of a major progress in the treatment of GB...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Mol Sci
Asıl Yazarlar: Nguyen, Ha S., Shabani, Saman, Awad, Ahmed J., Kaushal, Mayank, Doan, Ninh
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2018
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6032212/
https://ncbi.nlm.nih.gov/pubmed/29899215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19061765
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller